Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME)

• Published in: Journal of the American College of Cardiology Vol. 68; no. 16; pp. 1815 - 1817
• Main Authors: Gentry, James L., MD, Mentz, Robert J., MD, Hurdle, Melissa, BA, Wang, Andrew, MD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 18.10.2016; Elsevier Limited
• Subjects: Aged; Angina pectoris; Angina Pectoris - drug therapy; Angina Pectoris - etiology; Cardiology; Cardiomyopathy; Cardiomyopathy, Hypertrophic - complications; Cardiovascular; Cardiovascular Agents - therapeutic use; Clinical outcomes; Dyspnea; Dyspnea - drug therapy; Dyspnea - etiology; Female; Heart failure; Humans; Internal Medicine; Ischemia; Male; Middle Aged; Pilot Projects; Quality of life; Questionnaires; Ranolazine - therapeutic use; United States > US; Kansas City Missouri
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2016.07.758

The results are notable for significant clinical improvements in several disease-specific health status measures including less angina and heart failure symptoms and an improvement in health-related quality of life. Physical limitation 61.7 ± 20.6 72.0 ± 20.6 0.16 Symptom stability 43.2 ± 16.2 72.7 ± 26.1 0.014 Symptom frequency 56.4 ± 20.6 72.2 ± 20.0 0.035 Symptom burden 55.3 ± 29.4 75.0 ± 24.2 0.037 Total symptom score 55.9 ± 24.2 73.6 ± 21.3 0.028 Self-efficacy 78.4 ± 21.7 85.2 ± 14.6 0.37 Quality of life 39.4 ± 26.6 65.2 ± 25.8 0.008 Social limitation 46.0 ± 31.5 66.1 ± 31.2 0.18 Overall summary 51.2 ± 22.3 69.8 ± 23.5 0.032 Clinical summary 58.8 ± 20.9 74.0 ± 20.5 0.047 Table 1 Baseline and Follow-Up Characteristics of Patients Completing the RHYME Study Values are mean ± SD or n (%).